Related Experiment Video
Updated: Feb 14, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
Fate of Antibody-Drug Conjugates in Cancer Cells
Cécile Chalouni1, Sophia Doll2
1Department of Pathology, Genentech, San Francisco, CA, USA. cecilec@gene.com.
Abstract:
Antibody-Drug Conjugates (ADCs) are a class of cancer therapeutics that combines antigen specificity and potent cytotoxicity in a single molecule as they are comprised of an engineered antibody linked chemically to a cytotoxic drug. Four ADCs have received approval by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) and can be prescribed for metastatic conditions while around 60 ADCs are currently enrolled in clinical trials. The efficacy of an ADC greatly relies on its intracellular trafficking and processing of its components to trigger tumor cell death. A limited number of studies have addressed these critical processes that both challenge and help foster the design of ADCs. This review highlights those mechanisms and their relevance for future development of ADCs as cancer therapeutics.
Insights
Antibody-Drug Conjugates (ADCs) are advanced cancer therapies. Understanding their intracellular trafficking and processing is key to improving ADC efficacy and designing next-generation cancer treatments.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Antibody-Drug Conjugates (ADCs) represent a significant advancement in cancer therapeutics, merging antibody-driven targeting with potent cytotoxic payloads.
- Currently, four ADCs are FDA and EMA approved for metastatic conditions, with approximately 60 more in clinical trials, underscoring their growing importance.
Purpose of the Study:
- This review focuses on the critical intracellular trafficking and processing mechanisms of ADCs.
- It aims to highlight how these processes influence ADC efficacy and present challenges and opportunities for future ADC design.
Main Methods:
- A comprehensive literature review was conducted.
- Key studies on ADC intracellular trafficking, processing, and their impact on cytotoxicity were analyzed.
Main Results:
- The efficacy of ADCs is critically dependent on the intracellular journey and breakdown of their components to induce tumor cell death.
- Limited research has explored these essential mechanisms, which are vital for optimizing ADC performance.
Conclusions:
- Understanding the intracellular mechanisms of ADCs is crucial for overcoming current limitations and advancing their development.
- This knowledge will guide the rational design of more effective Antibody-Drug Conjugates for cancer treatment.
Related Concept Videos
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Conjugated Proteins
Fates of Pyruvate
In aerobic organisms, pyruvate is metabolized via the citric acid cycle to produce reduced coenzymes NADH and FADH2. These coenzymes are then oxidized in the electron transport chain to produce ATP and, in the process, regenerate the NAD+ and FAD. As seen in some cell types and organisms, fermentation...
Conjugation
Mechanism of Conjugation
Personal Choice and Fate Attributions

